Safety and Effectiveness of Empagliflozin/Linagliptin FDC in Uncontrolled T2DM Patients with COVID-19 Infection

被引：0
|
作者：
Sengupta, Asoktaru
机构：
来源：
DIABETES | 2023年 / 72卷
关键词：
D O I：
10.2337/db23-1812-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1812-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real world assessment of effectiveness and safety of FDC of remogliflozin etabonate and Vildagliptin in T2DM patients
    Bhattacharyya, S.
    Katare, S.
    Khaladkar, K.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [2] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes (T2DM)
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2015, 64 : A302 - A303
  • [3] NETWORK META-ANALYSIS TO ASSESS THE RELATIVE EFFICACY AND SAFETY OF LINAGLIPTIN, EMPAGLIFLOZIN AND THE FIXED DOSE COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Daacke, I
    Kanters, S.
    Thorlund, K.
    Tebboth, A.
    VALUE IN HEALTH, 2016, 19 (07) : A667 - A667
  • [4] Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy
    Kumar, Amit
    Prakash, Akhouri Sukrit
    JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES, 2019, 34 (01): : 87 - 91
  • [5] COST EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH T2DM AND HIGH CV RISK IN CANADA
    Mettam, S. R.
    Bajaj, H.
    Kansal, A. R.
    Kandaswamy, P.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [6] Safety and Tolerability of Combinations of Empagliflozin/Linagliptin (EMPA/LINA) for 52 Weeks in Subjects with Type 2 Diabetes (T2DM)
    Patel, Sanjay
    Defronzo, Ralph A.
    Lewin, Andrew
    Liu, Dacheng
    Kaste, Renee
    Kohler, Sven
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2015, 64 : A326 - A327
  • [7] Safety and Tolerability of Linagliptin and Metformin in Combination for Patients with Type 2 Diabetes Mellitus (T2DM)
    Ross, Stuart A.
    Haak, Thomas
    Patel, Sanjay
    Thiemann, Sandra
    Schumacher, Helmut
    Meinicke, Thomas
    DIABETES, 2014, 63 : A277 - A277
  • [8] Letter to the Editor: Fasting plasma glucose associated with mortality rate in T2DM patients with COVID-19 infection
    Kong, Wen
    Zhang, Jiaoyue
    Xu, Ying
    Li, Li
    Li, Qin
    Yang, Li
    Wang, Hanyu
    Hu, Yu
    Chen, Lulu
    Pan, An
    Zeng, Tianshu
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 108
  • [9] Glucose-lowering treatments and COVID-19 mortality in T2DM
    Hadjadj, Samy
    Wargny, Matthieu
    NATURE REVIEWS ENDOCRINOLOGY, 2021, 17 (07) : 387 - 388
  • [10] Glucose-lowering treatments and COVID-19 mortality in T2DM
    Samy Hadjadj
    Matthieu Wargny
    Nature Reviews Endocrinology, 2021, 17 : 387 - 388
12345